$RKLB $38C 07/18/2025 was filled at $2.12, now trading at $10.00 — that’s a 371% return. They’re sitting on millions in just One Week. Check out that opening Flow on 7/7

$RKLB over +70% in 3 weeks since I posted insane gains for a stock in such a short period of time on size sold all of my position here

$RKLB +50% this is some crazy numbers for the stock market on good size. I keep cashing out more and more from crypto and putting into stocks FYI, stocks are so stupid easy it's enjoyable

🛰️ $RKLB $38C 07/18/2025 calls alerted below caught a +30% intraday move today via UW alert

trading stocks is so easy mode it's actually retarded I'm not joking even a 5 year old could make money in this market

Missing Pengu and few other bangers But this is ALT season. And has been going on for four years while random morons on CT are waiting for some 2017 VC scam coin to pump in a “alt season” This is literally why Weekly Wizdom has killed it last 2 years

$RKLB looks good for $44

Earnings Summary & Key Updates 🔸 Monster Beverage ( $MNST) Q4 EPS: $0.38 (vs. est. $0.40); Revenue up 4.7% YoY to $1.81B (vs. est. $1.8B). Gross profit margin improved to 55.5% (Non-GAAP). Operating income up 7.9% to $517.9M (Non-GAAP). 🔸 Tesla ( $TSLA) applied for a permit in California linked to chauffeur services, a step toward regulatory approval for its planned robotaxi service. 🔸 Array Technologies ( $ARRY) – Q4 adj. EPS: $0.16 (vs. est. $0.17), adj. EBITDA: $45.2M (vs. est. $47.6M), revenue: $275.2M (vs. est. $268.5M), gross margin: 28.5%. Q1 revenue guidance: $260M-$270M (vs. est. $292.17M), FY revenue: $1.05B-$1.15B (vs. est. $1.127B). 🔸 Bloom Energy ( $BE) – Q4 adj. EPS: $0.43 (vs. est. $0.30), revenue: $572.4M (vs. est. $508.28M), gross margin: 38.3%, op. margin: 18.3%. FY revenue guidance: $1.65B-$1.85B (vs. est. $1.671B), adj. op. income: $135M-$165M (vs. est. $126.44M). 🔸 EOG Resources ( $EOG) – Q4 adj. EPS: $2.74 (vs. est. $2.57), revenue: $5.59B (vs. est. $5.95B). Oil & gas volumes and costs outperformed guidance. Announced $6.2B 2025 capital plan to grow oil production 3% and total production 6%. Entered a strategic agreement with Bapco Energies in Bahrain. 🔸 Sunrun ( $RUN) – Q4 revenue: $518.5M (vs. est. $537.9M). Installed 392 MWh of storage, up 78% YoY, exceeding guidance. Storage attachment rate: 62%. Q1 cash generation expected at $40M-$50M. 🔸 Talen Energy ( $TLN) – FY adj. EBITDA: $770M, adj. free cash flow: $283M, exceeding 2024 guidance midpoints. Reaffirmed 2025 guidance; 2026 outlook unchanged. 🔸 Tidewater ( $TDW) – Q4 revenue: $345.1M (vs. est. $340.1M), adj. EBITDA: $138.4M (in line with estimates). FY revenue guidance: $1.32B-$1.38B (vs. est. $1.44B), gross margin: 48%-50% (vs. est. 50.1%). 🔸 CubeSmart ( $CUBE) – Q4 AFFO/share: $0.68 (in line), adj. EPS: $0.45 (vs. est. $0.46), revenue: $231.4M (vs. est. $266.4M). FY AFFO/share guidance: $2.50-$2.59 (vs. est. $2.68), EPS: $1.40-$1.49 (vs. est. $1.76). 🔸 Green Dot ( $GDOT) – Q4 EPS: $0.40 (vs. est. $0.35), revenue: $455M (vs. est. $421.9M). FY25 EPS guidance: $1.05-$1.20 (vs. est. $1.50), adj. EBITDA: $145M-$155M. Expects embedded finance and money movement to drive 2025 growth. 🔸 Redfin ( $RDFN) – Q4 EPS loss: (-$0.29) (vs. est. -$0.23), revenue up 12% YoY to $244.3M (vs. est. $242.5M). Q1 revenue guidance: $214M-$225M (vs. est. $242.8M), Q1 net loss expected at ($94M-$83M). Q4 adj. EBITDA: $2.9M. 🔸 Rocket Companies ( $RKT) – Q4 adj. EPS: $0.04 (vs. est. $0.03), total revenue: $1.76B, adj. revenue: $1.2B (high end of guidance). Q1 revenue guidance: $1.17B-$1.325B. 🔸 Acadia Healthcare ( $ACHC) – Q4 adj. EPS: $0.64 (vs. est. $0.71), adj. EBITDA: $153.1M (vs. est. $171.4M), revenue: $774.2M (vs. est. $779M). FY revenue guidance: $3.3B-$3.4B (vs. est. $3.441B), adj. EBITDA: $675M-$725M (vs. est. $747.9M), adj. EPS: $2.50-$2.80 (vs. est. $3.35). 🔸 Iovance Biotherapeutics ( $IOVA) – Q4 EPS loss: (-$0.26) (vs. est. -$0.27), revenue: $73.7M (vs. est. $72.2M). Reaffirms FY25 total product revenue guidance of $450M-$475M. Amtagvi total revenue: $73.7M in Q4, $164.1M in FY24. 🔸 Natera ( $NTRA) – Q4 EPS: (-$0.41) (vs. est. -$0.42), revenue: $476.1M (vs. est. $428.6M). FY revenue guidance: $1.87B-$1.95B (vs. est. $1.819B), gross margin: 60%-64%. 🔸 Pacira BioSciences ( $PCRX) – Q4 EPS: $0.96 (vs. est. $0.83), revenue: $187.3M (vs. est. $185.4M). FY25 revenue guidance: $725M-$765M (vs. est. $747.6M), gross margin: 76%-78%, R&D expense: $90M-$105M, SG&A expense: $290M-$320M. 🔸 Progyny ( $PGNY) – Q4 adj. EPS: $0.42 (vs. est. $0.10), adj. EBITDA: $47.5M (vs. est. $41.8M), revenue: $298.4M (vs. est. $276.7M). Q1 revenue guidance: $300M-$318M (vs. est. $280.3M), FY revenue: $1.175B-$1.225B (vs. est. $1.159B), adj. EPS: $1.52-$1.62 (vs. est. $0.60). 🔸 RadNet ( $RDNT) – Q4 adj. EPS: $0.22 (vs. est. $0.20), adj. EBITDA: $75M (vs. est. $74.8M), revenue: $477.1M (vs. est. $461.8M). FY revenue guidance: $1.825B-$1.875B (vs. est. $1.979B), adj. EBITDA: $265M-$273M (vs. est. $309.3M), FCF: $70M-$80M. 🔸 Solventum ( $SOLV) – Q4 adj. EPS: $1.41 (vs. est. $1.32), revenue: $2.07B (vs. est. $2.05B). FY adj. EPS guidance: $5.45-$5.65 (vs. est. $5.49). 🔸 TransMedics Group ( $TMDX) – Q4 EPS: $0.19 (vs. est. $0.16), revenue: $121.6M (vs. est. $110.3M), gross margin: 59%. FY revenue guidance: $530M-$552M (vs. est. $528.6M). 🔸 Boeing ( $BA) & Safran – Assessing impact of a fire at Pennsylvania's SPS Technologies factory, seeking alternative suppliers. GE Aerospace (GE) taking steps to minimize disruption. 🔸 Archer Aviation ( $ACHR) – Q4 adj. EBITDA: -$94.8M, operating expenses up 16% YoY to $124.2M, net loss: -$198.1M (+82% YoY). Q1 adj. EBITDA loss guidance: -$95M to -$110M. 🔸 MasTec ( $MTZ) – Q4 EPS: $1.44 (vs. est. $1.26), revenue: $3.4B (+3.8% YoY, vs. est. $3.32B). Q1 EPS guidance: $0.34 (vs. est. $0.39). 2025 outlook: revenue $13.45B (+9% YoY), GAAP net income: $327M-$366M, adj. EBITDA: $1.10B-$1.15B. 🔸 Mosaic ( $MOS) – Q4 adj. EPS: $0.45 (vs. est. $0.57), revenue: $2.8B (vs. est. $2.92B). Missed estimates due to lower potash prices and sales. Q4 potash sales volume: 2.2M tonnes (-15% YoY), avg. price: $199/tonne (-18%). Potash revenue: $600M (-25%), adj. core profit: $95M (-24%). 🔸 Rocket Lab USA ( $RKLB) – Q4 adj. EBITDA: -$23.2M (vs. est. -$29.1M), revenue: $84M (vs. est. $130.6M). Q1 revenue guidance: $117M-$123M (vs. est. $135.7M), adj. gross margin: 30%-32%, adj. EBITDA: -$35M. 🔸 Autodesk ( $ADSK) – Q4 adj. EPS: $2.29 (vs. est. $2.14), revenue: $1.6B (vs. est. $1.632B), adj. EBIT margin: 37%. Q1 guidance: revenue $1.6B-$1.61B (vs. est. $1.598B), EPS $2.14-$2.17 (vs. est. $2.08). FY guidance: revenue $6.895B-$6.965B, adj. op margin 36%-37%, EPS $9.34-$9.67 (vs. est. $9.24). 🔸 Dell ( $DELL) – Q4 adj. EPS: $2.68 (vs. est. $2.52), revenue: $23.9B (vs. est. $24.57B). Q1 guidance: EPS $1.65 (vs. est. $1.83), revenue $22.5B-$23.5B (vs. est. $23.72B). FY26 midpoint in line with consensus. Announced $10B stock buyback and 18% dividend increase to $2.10. 🔸 DoubleVerify ( $DV) – Q4 adj. EBITDA: $73.8M (vs. est. $76.48M), revenue: $190.6M (vs. est. $196.9M). Q1 guidance: revenue $151M-$155M (vs. est. $157.5M). FY revenue expected to grow ~10% (vs. est. 12.59%). 🔸 Duolingo ( $DUOL) – Q4 EPS: $0.28 (vs. est. $0.48), revenue: $209.6M (vs. est. $205.4M), paid subs: 9.5M, DAU: 40.5M, MAU: 116.7M. Q1 guidance: revenue $220.5M-$223.5M (vs. est. $221.07M). FY guidance: revenue $962.5M-$978.5M (vs. est. $965.88M). 🔸 Elastic ( $ESTC) – Shares surged on strong Q3 results: adj. EPS $0.63 (vs. est. $0.47), adj. op income $64M (vs. est. $55.4M), revenue $382.5M (vs. est. $368.7M). Q4 guidance: revenue $379M-$381M (vs. est. $374.2M), adj. op margin ~13.5%, adj. EPS $0.36-$0.37 (vs. est. $0.31). 🔸 HP ( $HPQ) – Q1 adj. EPS: $0.74 (in line), revenue: $13.5B (vs. est. $13.36B). Growth driven by strong personal systems segment: revenue up 5% to $9.2B, commercial PC revenue up 10%. Q2 guidance: EPS $0.75-$0.85 (vs. est. $0.86). FY EPS: $3.45-$3.75 (vs. est. $3.59). 🔸 iHeartMedia ( $IHRT) – Q4 adj. EBITDA: $246M (vs. est. $291.3M), revenue: $1.118B (vs. est. $1.166B). Q1 guidance: adj. EBITDA $100M-$110M (vs. est. $120.25M). 🔸 NetApp ( $NTAP) – Q3 EPS: $1.91 (in line), revenue: $1.64B (vs. est. $1.7B). Q4 guidance below midpoint. FY25 guidance: EPS $7.17-$7.27 (vs. est. $7.33), revenue $6.49B-$6.64B (vs. est. $6.67B). 🔸 SoundHound AI ( $SOUN) – Q4 adj. EPS: -$0.05 (vs. est. -$0.10), revenue: $34.5M (vs. est. $33.69M). FY guidance: revenue $157M-$177M (vs. est. $165.26M).

RECAP • $CAVA: Q3 EPS $0.15, above expectations of $0.11; sales up 39% to $243.8M; FY guidance for restaurant comp sales at 12.5%, up from 8.5-9.5%, and EBITDA at $123M. Plans to increase restaurant openings and margins. • $FLUT: Q3 adjusted EBITDA up 74% to $450M; revenue up 27% to $3.25B; raised full-year forecasts for EBITDA and revenue, expecting 35% profit increase. • $CART: Q3 EPS $0.42 vs. $0.22 est.; revenue $852M vs. $844M est.; Q4 EBITDA guidance $230M-$240M, below estimate; increased buyback program by $250M. • $LNW: Q3 net income $64M, less than $100.7M expected; revenue $817M, slightly below $821.21M; continues double-digit revenue growth. • $RIVN: Formed JV with Volkswagen for tech development, with VW investing up to $5.8B by 2027. • $SAVE: Shares fell -60% due to bankruptcy filing rumors, currently negotiating with creditors. • $TSLA: Recalling 2,431 Cybertrucks due to potential power loss issues, marking the sixth recall this year. • $MODG: Q3 EPS loss at -$0.02, better than -$0.16 expected; revenue $1.01B, above $983M forecast; adjusted full-year revenue and EBITDA guidance downwards. • $OXY: Q3 adj EPS $1.00, above $0.74 expected; production rose 15.7% to 1.41 Mboepd due to CrownRock acquisition, despite lower prices; Q4 production expected at 1.43-1.47 Mboepd. • $RKLB: Q3 EPS ($0.10) vs. ($0.11) est., with revenues at $104.8M vs. $102.3M est.; Q4 revenue guidance $125-135M, with a new multi-launch deal for Neutron. • $DHT: Q3 EPS $0.22, topping $0.20 estimate; adjusted EBITDA $70.4M vs. $66.4M expected, on slightly lower than expected adjusted revenues of $92.64M. • $AB): Reported a 2% drop in AUM to $793B in October 2024 from $806B due to market downturn, with no net inflows or outflows. • $MARA: Q3 revenue increased by 34% to $131.6M, missing the forecast of $137.5M. • $PAY: Q3 EPS was $0.15 compared to $0.09 expected; revenue hit $231.6M against $190.6M estimated. They foresee Q4 revenue at $215M-$220M and FY24 at $829M-$834M, both above consensus. • $RKT: Q3 adjusted EPS met estimates at $0.08; adjusted EBITDA was $286M, above the $272.33M expected, with revenues at $1.323B, beating the forecast. They anticipate a drop in Q4 revenue to $1.05-1.2B. • $WULF: Q3 adjusted EBITDA was $6M, below the $11.2M prediction, with revenues at $27.1M, not meeting the $34.28M estimate. • $AMGN: Clarified no link between MariTide use and bone density changes, despite earlier reports of potential loss. The company remains confident in the drug's future. • $ICUI: Q3 adjusted EPS $1.59 vs $1.25 expected; revenue $589.131M vs $574.7M forecast, with a gross margin of 34.8%. FY guidance raised for EPS and EBITDA. • $NTRA: Q3 EPS ($0.26) vs ($0.57) expected, revenue $439.8M vs $361.45M; FY revenue guidance set at $1.61-1.64B, above consensus. • $PGNY: Q3 EPS $0.11, below $0.13 expected; revenue $286.625M vs $296.88M; full-year revenue and EBITDA guidance below market expectations. • $SGMO: Q3 EPS $0.04, better than ($0.03) expected; revenue $49.41M vs $17.94M forecast. Adjusted annual operating expenses expected to be $125-145M. • $SYRS: Shares dropped -80% after the SELECT-MDS-1 trial for tamibarotene failed to meet its primary endpoint, leading to discontinuation of the study. • $DOX: Q4 adjusted EPS $1.70, matching expectations, with revenue at $1.264B, slightly above the $1.263B estimate. • $PLUS: Q2 adjusted EPS $1.36, below $1.39 expected; revenue $515.2M vs $576.5M forecast. Full-year sales guidance unchanged, but adjusted EBITDA expected at $195-205M. • $IAS: Q3 EPS $0.10 vs $0.07 expected, with revenue at $133.528M and a gross margin of 80%. Q4 revenue and EBITDA guidance were both below expectations. • $SOUN: Q3 adjusted EPS ($0.04) vs ($0.07) expected; revenue $25.1M, above $23.02M estimate. Set FY24 and FY25 revenue targets. • $SWKS: Q4 adjusted EPS $1.55 vs $1.52, revenue $1.025B, nearly matching estimates. Q1 guidance for revenue and EPS below expectations. • $SPOT: Q3 revenue growth of 19% to €3.99B missed the €4.02B estimate; profit margin improved. Q4 revenue guidance below expectations but operating income and MAUs on target. • $SMCI: Announced delay in filing Q3 2024 quarterly report due to ongoing issues with the annual report. • $ZI: Q3 adjusted EPS $0.28, surpassing the $0.22 estimate; revenue $303.6M vs $299.38M. Q4 revenue guidance in line with estimates, but EPS slightly below consensus.

collateral: $SOL stocks: $COIN, $HOOD, $GLXY, $RKLB memes: $WIF, $MOG, $MEW, $MOTHER, $MICHI, $SCF altcoins: go do the homework perps: @HyperliquidX retirement: 2027